STUDY OF BIOEQUIVALENCE OF MAGNESIUM AND SODIUM VALPROATES

被引：14

作者：

BALBI, A

SOTTOFATTORI, E

MAZZEI, M

SANNITA, WG

机构：

[1] SUNY STONY BROOK,DEPT PSYCHIAT,STONY BROOK,NY 11794

[2] UNIV GENOA,IST NEUROFISIOPATOL,CTR FARM NEUROPSICOATT,I-16132 GENOA,ITALY

来源：

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 1991年 / 9卷 / 04期

关键词：

MAGNESIUM VALPROATE; SODIUM VALPROATE; BIOEQUIVALENCE; SERUM ANALYSIS; REVERSED-PHASE HPLC;

D O I：

10.1016/0731-7085(91)80200-S

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

The in vivo bioavailability of magnesium valproate (500 and 1000 mg) enteric-coated tablets has been compared with that of sodium valproate (Depakine(R)) (500 and 1000 mg) enteric-coated tablets. The two preparations were found to be bioequivalent; magnesium valproate appeared to be a drug without bioavailability problems and with reduced intersubject variability, compared with that of sodium valproate. A reversed-phase HPLC method for the determination of valproates is described.

引用

页码：317 / 321

页数：5

共 12 条

[1] BORGES LF, 1978, EPILEPSIA, V19, P81
[2] GARDNERTHORPE C, 1977, ANTIEPILEPTIC DRUG M
[3] Guelen PJM, 1978, RATIONAL ANTIEPILEPT
[4] CLINICAL PHARMACOKINETICS OF VALPROIC ACID
GUGLER, R
UNRUH, GEV
[J]. CLINICAL PHARMACOKINETICS, 1980, 5 (01) : 67 - 83
[5] KLOTZ U, 1977, CLIN PHARMACOL THER, V21, P736
[6] LEVY RH, 1984, EPILEPSIA S1, V25, P1
[7] MEASUREMENT OF VALPROIC ACID IN SERUM AS THE 4-BROMOPHENACYL ESTER BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
MOODY, JP
ALLAN, SM
[J]. CLINICA CHIMICA ACTA, 1983, 127 (02) : 263 - 269
[8] RALL TW, 1985, PHARMACOL BASIS THER, P461
[9] SCHNEIDER H, 1975, CLIN PHARM ANTIEPLIE
[10] SWARTZ H, 1979, INVEST MED INT, V6, P247

← 1 2 →